in this story
According to one researcher, it took just seven years for GLP-1 drugs like Ozempic to overtake insulin as the second most common treatment for type 2 diabetes. new report By market research and analysis firm Trilliant Health.
According to Trilliant's 2024 Trends Shaping the Health Economics report, GLP-1 drugs have gone from being the eighth most common drug regimen for type 2 diabetes in 2018, one year after Ozempic was launched in the United States, to By 2023, it has risen to the second most common drug regimen. Insulin fell to third place last year.
Metformin regulates blood sugar levels by reducing the amount of glucose released by the liver and helping the body absorb more glucose from the bloodstream., has held the top spot as the leading treatment for type 2 diabetes for the past six years.
GLP-1 drugs, which act similar to hormones that regulate blood sugar levels and suppress appetite, have recently become very popular for their slimming effects.
In 2023, Ozempic will be novo nordisk It is a best-selling drug, with sales reaching 31 billion Danish kroner ($14 billion).
The surge in demand for these treatments has led to Novo Nordisk (NVO-0.82%) and its rival Eli Lilly (lily-1.38%), the manufacturer of Mounjaro, The world's most valuable pharmaceutical company. Morgan Stanley (M.S.+0.25%) Analysts expect the global market for these drugs, known as GLP-1/GIP therapeutics, to reach $105 billion by 2030.
And their influence continues to grow.
Trilliant's report says GLP-1 could increase or decrease demand for other medical treatments such as gastrointestinal (GI) drugs and bariatric surgery. One year after patients started GLP-1 therapy, the proportion of patients with a gastrointestinal-related diagnosis increased by 1 percentage point to 11.3%, and the proportion of patients taking gastrointestinal-related medications increased by 1 percentage point. It increased by 3.7 points to 33%. According to Trilliant Health
Trilliant also predicted that up to $533.4 million in revenue could be lost if GLP-1 drugs replaced just 20% of bariatric surgery providers.
“As new treatments become available and new evidence is incorporated into clinical guidelines, some high-margin surgical procedures may be replaced by less invasive interventions or downstream demand may decline. ” is high,” the report states.
